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Introduction
The goal of the Georgia Sickle Cell Data Collection
(SCDC) Program is to improve the quality of life, life
expectancy, and the health of individuals with sickle
cell disease by developing and disseminating scientific
evidence to inform policies and practices.
This longitudinal data-collection effort builds on five
years of sickle cell disease surveillance in the state
created under cooperative agreements with the U.S.
Centers for Disease Control and Prevention (CDC) and
the National Heart, Lung, and Blood Institute’s Registry
and Surveillance System for Hemoglobinopathies
(RuSH) pilot project and the CDC’s Public Health
Research, Epidemiology, and Surveillance in Hemoglobinopathies (PHRESH) initiative.
Georgia collected data (2004-2008) from the following sources to develop its surveillance system for
hemoglobinopathies:1
•

State newborn screening program (source: Georgia Department of Public Health);

•

Death records (source: Georgia Department of Public Health);

•

Clinical data from the three comprehensive sickle cell centers in the state (Augusta University, Grady
Health System, and Children’s Healthcare of Atlanta);

•

Administrative claims data from Georgia’s Medicaid, Children’s Health Insurance Program, and the State
Health Benefit Plan (source for all three: Georgia Department of Community Health); and

•

Hospital and emergency department (ED) discharge data (source: Georgia Hospital Association under a
data-sharing agreement with Georgia Department of Public Health).

The current goals are to continue using and improving upon developed methods and data sources for
understanding sickle cell disease at the population level in Georgia, including extending the database
to include longitudinal data through 2016 (or most recent year available). This unique data set enables
examination of individual-level patient data for every health care system encounter for more than 10,000
patients over 13 years. The ability to collaborate with the SCDC project in California, and possibly other states
in the future, brings additional power to the capabilities of the data set in its ability to identify trends and
inform changes in both policy and practice.
The following plan represents our best-informed strategy for using the data over the next three years. It is
based on substantial input from sickle cell disease stakeholders, including affected populations, policymakers,
providers, and payers.
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Sickle Cell Disease Overview

National Institutes of Health, National Human Genome Research Institute. Sickle
cell disease [Photograph]. Talking Glossary of Genetic Terms. Retrieved from
https://www.genome.gov/glossary/index.cfm?id=184

Sickle cell disease (SCD) describes a group of
inherited blood disorders that affect hemoglobin,
a protein in red blood cells that is responsible for
carrying oxygen through the body. A single gene
mutation causes people with SCD to have abnormal
hemoglobin. Normal hemoglobin has a disc shape
that is flexible and can move throughout the body’s
blood vessels to deliver oxygen. Instead of healthy,
disc-shaped hemoglobin, those with SCD have sickle
hemoglobin that forms stiff rods with a crescent
shape. These sickle-shaped cells are not flexible
and can stick to the walls of blood vessels, causing
a blockage that slows or stops the flow of blood.2
This blockage prevents oxygen from reaching tissues
and organs. This can cause severe pain and fatigue,
organ damage, strokes, and even death.

Distribution of sickle cell disease
Sickle cell is a rare disease, affecting approximately 100,000 people in the United States.3  Overall, the
prevalence of SCD has increased in the United States due to growth of at-risk populations, as well as
improvements in patients’ life expectancy.
In the United States, most people with SCD have African ancestry or identify themselves as black, but SCD
also affects other groups, including those of Hispanic origin and people of Middle Eastern, Asian, Indian, and
Mediterranean descent.4
SCD occurs among approximately one of every 365 black or African-American births and in about one of every
16,300 Hispanic-American births.3 Considerably more are born with sickle cell trait, meaning they are usually
unaffected but could pass the condition to their offspring.5

Life expectancy
Once considered a childhood disease because of
limited survival into adulthood, there has been great
improvement in early SCD survival due to preventive
care (e.g., prophylactic penicillin and vaccines),
disease-remitting therapy (e.g., hydroxyurea), and
use of comprehensive care models.3, 6, 7, 8

6

In 1973, the average life span of a person with SCD in
the United States was only 14 years, with 20 percent
of the deaths occurring in the first two years of life
and one-third occurring before the fifth year of life.9
More recently, population-based surveillance data
from California and Georgia for years 2004 through
2008 show the all-cause mortality rate for the SCD
population aged birth through 4 years was lower
than the all-cause mortality rate among AfricanAmericans and similar to the total population’s allcause mortality rates, but the rate was higher among
those with SCD, compared to both the AfricanAmerican and total population rates from ages 5
years through 74 years.10

Figure 1. Individuals with SCD in Georgia by Age

U.S. Department of Health and Human Services, Centers for Disease Control and
Prevention. (2013). Age distribution of individuals with SCD in Georgia identified by
RuSH [Graph]. Sickle Cell Disease in Georgia. Retrieved from https://www.cdc.gov/
ncbddd/sicklecell/documents/scd_in_ga_prov.pdf

The life expectancy of a person with SCD is now over
40 years.10, 11  Among people with SCD, the average
age of death was about 43 years for females and 41
years for males. About one in sixth deaths occurred in those under 25 years of age, and nearly half of all deaths
occurred in those over 44 years of age.10
While comprehensive care for children with SCD has been linked to improved survival, the lack of
comprehensive care for many adults with SCD may help explain the overall increased mortality rate for this
population compared to the general U.S. population and African-American population.

Genetics of sickle cell disease
While SCD is a rare disease in the number of total people affected, it is one of the most common diseases
caused by a single gene mutation. The most severe form of SCD, hemoglobin SS disease, occurs when the
gene for sickle hemoglobin (hemoglobin S) is inherited from both parents. When only one hemoglobin S gene
is inherited, the person is a carrier for SCD, or has sickle cell trait. While carriers can pass the hemoglobin
S gene to their offspring, most with sickle cell trait are healthy and asymptomatic for SCD, although some
complications have been documented.12
There are additional genetic forms of SCD, with varying severity:13, 14, 15
•

Hemoglobin SC — A hemoglobin S gene is inherited from one parent along with another abnormal
hemoglobin gene, hemoglobin C. Hemoglobin SC is usually a milder form of SCD.

•

Hemoglobin Sβ-thalassemia — In this form of the disease a hemoglobin S gene is inherited from one
parent, while a gene for β-thalassemia, another type of anemia, is inherited from the other parent.
β-thalassemia has two forms, “0” and “+.” Hemoglobin Sβ0 thalassemia is a more severe form of SCD,
while Hemoglobin Sβ+ thalassemia is a milder form of SCD.

•

Hemoglobin SD, SE, SO — These forms of SCD inherit one hemoglobin S gene as well as a gene for
another abnormal type of hemoglobin (D, E, or O).
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Diagnosis
SCD is diagnosed with a blood test. However, since
young children with SCD are at an increased risk of
health problems, even in infancy, early diagnosis
and treatment are important. In the United States,
SCD is most often diagnosed at birth during routine
newborn screening at the hospital. Every state in the
United States, the District of Columbia, and the U.S.
territories requires that all newborn babies receive
screening for SCD.16  If a child has SCD, parents are
notified immediately, before the child has symptoms.
Diagnosis in Georgia
The Georgia Newborn Screening Program ensures that as of January 1998 every newborn in Georgia is
screened for 31 heritable disorders for prompt identification and treatment, including SCD.17
The Georgia Newborn Screening Program of the Georgia Department of Public Health is responsible for
administering newborn screening, including the oversight of follow-up programs; monitoring and evaluating
newborn screening practices; managing electronic data surveillance and tracking systems, including
maintenance of long-term results; facilitating communication between practitioners, birth hospitals, laboratory
personnel, and follow-up teams; providing ongoing education for practitioners; and reporting results to state
and federal officials and to the public.
Following a positive hemoglobin screening result, the American Academy of Pediatrics recommends that
positive screens be confirmed by 3 months of age, as early diagnosis of SCD is crucial in reducing the morbidity
and premature death associated with the disease.18 In Georgia, the newborn screening program contracts with
three teams for follow-up of positive screens.17 Children’s Healthcare of Atlanta provides follow-up for positive
results in the Metro Atlanta counties, while Augusta University provides follow-up for all other counties. The
teams report abnormal results to the health care provider of record and parents, ensure timely confirmatory
testing, and provide education and counseling to families. (Confirmatory testing and associated family studies
for hemoglobinopathy are provided free of charge.) Confirmed cases are referred to the Children 1st program
at the Georgia Department of Public Health for determination of eligibility for child health intervention
services.
The Sickle Cell Foundation of Georgia is the third follow-up entity in Georgia, and it is responsible for followup of abnormal hemoglobin results that suggest a carrier or “trait” status as a result of inheriting a single
hemoglobin S gene.

Complications
SCD is a lifelong illness. The severity of the disease varies widely from person to person and is not fully
explained by genetics. Triggers for exacerbations and complications are also not fully understood, although
certain self-care factors (e.g., hydration) and possibly some environmental factors (e.g., altitude, climate, and
air quality) play a role.19, 20, 21, 22, 23
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Most SCD-related complications result from the
blockage of blood vessels from stuck, sickled
hemoglobin S. The lack of oxygen can cause organ
damage, commonly seen in the spleen, lungs,
eyes, heart, kidney, liver, gallbladder, and joints.13,
24
Increasingly, it is recognized that comprehensive
care with a focus on preventive efforts can reduce
complications.13
The most common complications include pain crises that often require hospitalization; debilitating chronic pain
that also can lead to high health care utilization; anemia, often severe, due to the more frequent breakdown
of fragile, sickled cells; life-threatening infections resulting from SCD-related spleen damage; and stroke, even
in young children.13, 25, 26, 27, 28, 29 Other complications can include delayed growth, pregnancy complications,
cognitive problems, and mental health issues.30

Care and treatment
SCD patients are encouraged to see their SCD care providers regularly — every three to 12 months.31  Routine
visits can include examination and screening, prophylactic medicines and immunizations, diagnostic testing,
and education of families about the disease and what to watch out for. Increased use of regular screenings and
preventive measures have decreased infections, complications, and death.13, 32, 33, 34, 35
Measures that have become the standard of quality care include these:
•

Prophylactic penicillin is recommended in children to decrease the rates of life-threatening infections.36

•

Immunizations, including conjugated pneumococcal, meningitis, and influenza type B, also reduce
serious infections.7

•

Regular screening with transcranial Doppler (TCD) can identify stroke risk, particularly in children
between the age of 2 and 16 years.37, 38, 39, 40

•

Regular blood transfusions for those at risk of stroke have also decreased the rate of strokes and
premature death.33, 35

•

Treatment with hydroxyurea decreases the number and severity of pain episodes by increasing the
amount of fetal hemoglobin (hemoglobin F) in the blood, providing some protection against the effects
of hemoglobin S.41, 42, 43, 44, 45

•

Stem cell transplants are the only cure for SCD, but they are limited in their use to certain targeted SCD
populations.46, 47

Other examinations and screening, including eye examinations, pulmonary hypertension screening, and
cognitive screening, can identify and treat SCD-related complications earlier.
Unfortunately, despite a growing body of evidence of the benefit of these care and treatment measures,
they are not fully utilized.32  Enhanced surveillance of utilization and quality practice can inform payers’ and
providers’ efforts and ultimately yield enhanced outcomes for patients with SCD.
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New treatments forthcoming
The landscape of care and treatment for those
with SCD is poised to improve in the coming years.
Pharmaceutical companies are currently testing
dozens of compounds in clinical trials for SCD and
related conditions. The SCD community is optimistic
that these treatments will lead to increased life
expectancy, lower health care costs, and improved
quality of life.49
The compounds in development, as well as drugs
originally developed for other purposes now being
investigated in SCD, have multiple mechanisms
of action. These include increasing production
of hemoglobin F, targeting oxidative injuries and
inflammation, and reducing cell adhesion among
sickled cells.13, 50 Longitudinal SCD data can better inform trials of these drugs by providing a baseline measure
of SCD utilization and outcomes to which improved treatment-related outcomes can be compared.
Transitioning care
As noted, decades ago the most devastating consequences of SCD were experienced in childhood. Now,
with advances in care, the deleterious effects of SCD are being borne most heavily by adolescents and young
adults. Some of these ill effects are directly related to the disease — the longer one has lived with SCD, the
more likely organ damage and additional disabilities have occurred. Additionally, adolescents and young
adults are transitioning toward independence; this transition period has been shown to negatively affect selfmanagement of the condition.
Rates of ED and hospital utilization are particularly high among adults with this disease. Availability of quality
care, lack of insurance, and distance to care pose barriers to adult access to the comprehensive care models
developed for the pediatric population.51 These challenges are particularly profound during the transition years
between pediatric and adult care, when increased rates of SCD-related complications and mortality have been
seen among SCD patients.51, 52 Throughout the nation there is a known shortage of hematologists trained and
willing to care for adult SCD patients.53

Past Sickle Cell Disease Surveillance
The only existing universal hemoglobinopathy screening and reporting activities in the United States are statebased newborn screening programs. Screening for SCD has been included on all 50 states’ newborn screening
panels since 2006. However, researchers note variability across newborn screening programs with regard
to the states’ public health role in follow-up for detected SCD, as well as use of reported data for statewide
planning, quality assurance, and policy development functions.54 Additionally, newborn screening does not
capture those with SCD that move from another state, those born outside of the United States, or older
individuals born prior to implementation of universal screening.
There have been calls for an improved system of data collection in order to accurately assess the number
of individuals with SCD nationwide, understand the impact of SCD on the health care system, and
strengthen development of comprehensive systems of care for those affected by SCD.1, 3, 54 A comprehensive
10

understanding of the impact of hemoglobinopathies
in the United States is important to health care
providers, researchers, payers, and policymakers.
Experts in SCD recognize that coordinated data
collection has the potential to improve the
understanding and treatment of SCD. Over the past
several years, multiple stakeholders have identified
the need for improved data collection as a priority.

Figure 2. Map of RuSH Sites

In 2007, the American Society of Pediatric
Hematology/Oncology Sickle Cell Summit identified
population-based surveillance to measure outcomes
as one of five major areas of opportunity for
improving SCD care.55  In 2008, the National Institutes
of Health convened the Consensus Conference
U.S. Department of Health and Human Services, Centers for Disease Control
on Hydroxyurea Treatment for Sickle Cell Disease,
and Prevention. (2016). [Map of the U.S. showing 7 RuSH sites]. Registry and
which specifically called for an SCD surveillance
Surveillance System for Hemoglobinopathies (RuSH). Retrieved from https://www.
cdc.gov/ncbddd/hemoglobinopathies/rush.htm
system containing demographic, laboratory, clinical,
treatment, and outcome information.56  As a result of
these meetings, the National Institutes of Health’s National Heart, Lung, and Blood Institute and the Division of
Blood Disorders at the CDC collaborated to work toward state-based surveillance for SCD and thalassemia.1

RuSH
The Registry and Surveillance System for Hemoglobinopathies (RuSH) began as a pilot project in 2010 under
a cooperative agreement between CDC and the National Heart, Lung, and Blood Institute with seven states
to develop and systematically test a multisource surveillance system. California, Florida, Georgia, Michigan,
New York, North Carolina, and Pennsylvania participated. According to 2008 census data, these seven states
combined represented approximately 38% of the total U.S. population, 42% of the black population, 54% of
the Asian population, and 49% of the Hispanic population in the country.1
The overall purpose of RuSH was to collect state-specific, population-based data on people with SCD and
thalassemia, with the long-term vision that the knowledge gained would result in a better understanding of
the conditions and, ultimately, improve the lives of individuals with hemoglobinopathies. Specific objectives
included:57
•

Identifying all individuals in each state with an SCD or thalassemia diagnosis using pre-existing data
sources;

•

Determining how many people have SCD or thalassemia;

•

Developing plans for a national surveillance system to gain a greater understanding of the health status
and health practices of people living with SCD and thalassemia; and

•

Creating and disseminating health education materials to increase knowledge and awareness about SCD
and thalassemia among the general public.
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Each state used a unique combination of data
sources for the project, depending on the data
sets they were able to access. Newborn screening
records, hospital discharge data, ED records, death
records, clinical records, and state Medicaid claims
were used for case identification and/or as sources
of demographic, clinical, and health care utilization
data. While the original intent of RuSH was to devise
a standardized data-collection protocol, the same
methods could not be used by all states because
of the varying availability of data sets and the
identifying information contained within those data
sets.
RuSH in Georgia
In Georgia, RuSH data-collection efforts were led by the Georgia Health Policy Center at Georgia State
University on behalf of the Georgia Department of Public Health and in partnership with the Sickle Cell Disease
Foundation of Georgia and the comprehensive sickle cell centers at Children’s Healthcare of Atlanta, Grady
Health System (Atlanta), and Augusta University Medical Center (formerly Georgia Regents University Medical
Center).
Specific objectives in Georgia included determining the prevalence of hemoglobinopathies (SCD and
thalassemia) across the life span in the state, calculating the annual incidence of hemoglobinopathies in
Georgia, describing the demographics of the affected populations in Georgia, and developing and documenting
the infrastructure and methodology for data collection to support possible continuation or expansion of
surveillance efforts.
Georgia used data (2004-2008) from the following sources to develop its surveillance system for
hemoglobinopathies:1
•

State newborn screening program (source: Georgia Department of Public Health);

•

Death records (source: Georgia Department of Public Health);

•

Clinical data from the three comprehensive sickle cell centers in the state at Augusta University, Grady
Health System, and Children’s Healthcare of Atlanta;

•

Administrative claims data from Georgia’s Medicaid, Children’s Health Insurance Program, and the State
Health Benefit Plan (source for all three: Georgia Department of Community Health); and

•

Hospital and ED discharge data (source: Georgia Hospital Association under a data-sharing agreement
with Georgia Department of Public Health).

Identifiers are collected under the public health authority of the Georgia Department of Public Health and are
used for matching and deduplication only. Few data sources included Social Security numbers or Medicaid
identification numbers consistently. Therefore, deterministic matching of patients was not feasible for most
data sets in Georgia.1 Each data set was deduplicated and data sets were then matched, one at a time, using a
probabilistic algorithm that assigned differing weights to identifying variables, such as date of birth, patient’s
name, mother’s name (for children), sex, county, telephone number, and address.
12

•

Probable, or Level II, cases defined by administrative records of health care encounters consistent
with SCD (two or more health care encounters with SCD ICD code plus one or more SCD-associated
complication, treatment, or procedure within a five-year period). These probable cases included those
with a positive newborn screening test but no confirmatory testing; clinical determination from an SCD
comprehensive center; three or more SCD ICD codes from Medicaid, PeachCare, or the State Health
Benefit Plan data; or three or more SCD ICD codes from hospital and ED discharge data.    

•

Possible, or Level III, cases involved a smaller number of health care encounters with SCD ICD codes —
either sickle cell trait ICD code at two or more separate health care encounters plus one or more SCDassociated complications, treatments, or procedures, or a single health care encounter with an SCD ICD
code.

Key Findings from RuSH Analysis:1, 58
Demographics
•

There are 7,299 people in Georgia living with SCD (confirmed and probable cases).

•

People with SCD live in almost every county throughout Georgia.

•

Those living with SCD in Georgia range in age from newborns to people over 70 years old.

•

The vast majority (97% or more) of Georgia newborns with SCD are black or African-American, while
approximately 2% are Hispanic.

•

Roughly one out of every 295 black or African-American babies born in Georgia from 2004 through
2008 had some form of SCD.
Figure 3. Number of Individuals with SCD by County

U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2013).
Number of individuals with SCD in Georgia counties identified by surveillance [Graph]. Sickle Cell Disease
in Georgia. Retrieved from https://www.cdc.gov/ncbddd/sicklecell/documents/scd_in_ga_prov.pdf
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Health care utilization
•

There are documented health care visits for 94% of the identified 7,299 Georgia residents with SCD
between 2004 and 2008.

•

Of newborns with a positive screen for SCD from 2004 through 2008, 80% were later seen at one of
Georgia’s two pediatric sickle cell centers.

•

For 26% of individuals with SCD, there were no hospitalizations during the five-year period, and 16%
had no ED visits.

•

Hospital visits, especially those to the ED, increased considerably after childhood. Children aged 0-19
years averaged four ED visits over the five years, while those aged 20-49 years had more than 15
emergency visits over the same period.
Figure 4. Average Number of Hospital Encounters per Individual with SCD, by Age Group, 2004-2008

U.S. Department of Health and Human
Services, Centers for Disease Control
and Prevention. (2013). Average number
of hospital encounters per individual
with SCD, by age group, 2004-2008
[Graph]. Sickle Cell Disease in Georgia.
https://www.cdc.gov/ncbddd/sicklecell/
documents/scd_in_ga_prov.pdf

Case definition
RuSH established three levels of case definitions for SCD based on laboratory results and International
Classification of Diseases, Clinical Modification, Ninth Revision (ICD-9-CM) codes.1 Developing these case
definitions was a key task and evolved as results were studied and definitions were validated:
•

Confirmed, or Level I, cases defined by laboratory confirmation of SCD genotype. Laboratory results
could be established either through confirmatory newborn screening testing or through genetic and
laboratory testing at SCD comprehensive centers.

PHRESH
It was determined that the health care utilization and clinical data gathered during RuSH could serve as
the foundation for the development of an ongoing, longitudinal SCD surveillance system. Expansion of the
information collected during the RuSH project began in 2012 with the launch of the CDC-sponsored Public
Health Research and Surveillance for Hemoglobinopathies (PHRESH) project. PHRESH focused on surveillance,
as well as health promotion and prevention of complications in those with hemogloinopathies living in three
partner states — California, Georgia, and Mississippi.
14

PHRESH’s primary goals included:59
•

Developing a monitoring program within a defined geographic area that provides accurate information
on the burden of disease — how the disease impacts individuals and communities.

•

Promoting health and preventing complications by improving the quality of care for people with
hemoglobinopathies, with a particular focus on vaccinations, early and continuous screening (e.g., TCD
screening), and the use of appropriate treatments (e.g., hydroxyurea). These focus areas align with
three of Healthy People 2020’s developmental objectives related to blood disorders.

Additionally, PHRESH sought to validate the RuSH methods and case definitions.
PHRESH in Georgia
Through its participation in PHRESH, Georgia extended its RuSH efforts of linking health care utilization to cases
with confirmed SCD diagnosis. During PHRESH, Georgia performed validation studies of the SCD case definition
developed during RuSH and examined the use of prevention strategies recommended for sickle cell patients.
Specifically, Georgia sought to —
•

Demonstrate the feasibility of a hemoglobinopathy surveillance program;

•

Validate case definitions and methodologies for collection of surveillance data on persons with
hemoglobinopathies;

•

Derive baseline estimates of the demographics and health service utilization of persons with
hemoglobinopathies, with priority attention to the Healthy People 2020 focus areas:
□□ Determine the vaccination coverage and vaccine-preventable disease level in individuals with SCD;
□□ Determine the proportion of children with Hb SS and Sβ° thalassemia screened by TCD
ultrasonography for stroke risk; and
□□ Determine the proportion of adults and children with Hb SS and Sβ° thalassemia receiving
hydroxyurea treatment.

•

Implement health promotion and prevention awareness strategies designed to improve patient care
quality:
□□ Develop and disseminate key health education materials for persons with hemoglobinopathies,
their families, and health care providers; and
□□ Conduct a needs assessment to identify gaps in knowledge and educational resources on
appropriate vaccinations, early and continuous screening for complications, and disease-modifying
therapies among patients and providers.

People with SCD are living longer, healthier lives, due in large part to advances in preventing disease-related
complications. One of the goals of the PHRESH project was to find out how well these advances are reaching
affected individuals in Georgia. Using the linked surveillance data, several briefs and academic papers were
published validating the use of the surveillance data to identify individuals with SCD as well as their receipt
of preventive therapies. Furthermore, educational materials highlighting prevention practices appropriate to
those with SCD were also disseminated to providers caring for SCD patients in Georgia.
For the SCDC project, both Georgia and California updated their case definitions based on these findings.
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Key Findings from Georgia PHRESH Work:60
Cases identified
•

Across data sets, 4,288 Level 1 (confirmed), 3,011 Level 2 (probable), and 9,208 (possible) cases were
identified in Georgia from 2004 through 2008.1

•

The majority (88%) of the 828 newborns who screened positive for sickle cell disease from 2004
through 2008 had a documented confirmatory diagnosis at follow-up (Level 1 case). The remaining 98
cases with positive screens, but no confirmatory test, were categorized as Level 2.

Provider information61

Based on surveys completed with 100 primarily pediatric medical practices in 48 counties that, according
to RuSH data, contain 85% of all confirmed SCD cases in Georgia:
•

SCD patients were seen in 84 of 100 surveyed medical practices;

•

Only seven practices had a sickle cell specialist on staff;

•

Most respondents said they refer their patients with SCD to specialists to manage all aspects of sickle
cell care; however

•

Sixteen respondents said there was no such specialist within a one-hour drive, or they were not
aware of one.

Health care utilization32
•

Hydroxyurea was underutilized in Georgia from 2004 to 2008:
□□ Among confirmed cases with SCD types for which hydroxyurea has demonstrated benefit, the
portion meeting clinical criteria who received hydroxyurea was 38% (36% of children, 42% of
adults); and
□□ Overall, only 30% of individuals (29% of children, 32% of adults) who met the clinical criteria for
hydroxyurea treatment filled a prescription.

•

Initiation of TCD ultrasound screening and pneumococcal polysaccharide vaccination (PPV) in children
from 2004 to 2008 is suboptimal in Georgia:
□□ In a cohort of 125 Georgia toddlers with SCD, 77% received their first dose of PPV vaccine at 2
years of age; and
□□ Only 23% of these same toddlers received their first TCD screening for stroke risk at 2 years of
age, as recommended.

Validation studies32
•

Claims data appears useful to track use of TCD in children and yields similar results to chart review.

•

State-based immunization registries are the most complete source of tracking immunizations for
individuals with SCD, better than chart review and claims data.

•

Validation studies of the RuSH case definition found that a simpler definition of at least three SCDcoded encounters was just as effective as the original definition (two encounters with SCD diagnosis
codes and at least one encounter with an SCD-associated treatment, procedure, or complication) in
accurately identifing “probable cases” and reducing the number of missed cases.
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Based on a five-year surveillance period, using this updated case definition of at least three SCDcoded encounters to identify SCD in administrative data is 97% accurate in identifying true cases
while only missing approximately 4% of cases.62

Sickle Cell Data Collection Program in Georgia
Data Collection
CDC is committed to continuing and expanding
prior SCD surveillance activities. With donations
from Pfizer Inc., Global Blood Therapeutics, and
Bioverativ, the CDC Foundation has enabled
CDC to partner with the California Rare Disease
Surveillance Program and the Georgia Health
Policy Center to revisit case definitions, update
surveillance data sets for the two states, and plan
and begin leveraging the data sets to improve
policies and practices on behalf of the sickle cell
patient population. As funds are available, CDC
plans to support additional states’ efforts. SCDC’s
overarching objective is to collect, synthesize,
and disseminate multisource, population-based,
63
longitudinal data on people with SCD. Ultimately, this can enable efforts to:
•

Establish a health profile of the SCD population;

•

Track changes in SCD outcomes over time;

•

Ensure that credible, scientifically sound information informs standards of care;

•

Inform policy and health care practices; and

•

Improve quality of life, life expectancy, and health among those living with SCD.

SCDC maintains the database and sources developed in RuSH but expands the years for which data is collected.
Having data from 2004 through 2016, this data set enables longitudinal examination of individual-level patient
data for every health care system encounter for more than 10,000 patients over 13 years.
While this unique data set is valuable to inform the above-stated goals, some limitations of the data should be
noted. The majority of the data is from administrative data sources (linked hospital discharge, EDs, Medicaid
claims, vital records, and newborn screening), rather than information collected directly from patients or
health care providers. Furthermore, the database doesn’t contain information from nonhealth agencies (e.g.,
school records), private data (nongovernment insurance claims or employment records), or patient-reported
measures (e.g., quality of life surveys).
California and Georgia are the two states currently participating in SCDC. The participants, along with CDC, plan
to expand dissemination of findings to date, including peer-reviewed publications, scientific presentations, and
briefs for targeted audiences based upon possible output measures, including demographics, health system
entry and exit points, health care utilization, complications, treatment, outcomes, and provider information.
Additionally, with additional funding, the program would like to expand to include other states.
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SCDC strives to improve health outcomes for people with SCD. By collecting and analyzing health information
of patients with SCD over time, the program can identify critical gaps in diagnosis, treatment, and access
to care for people with SCD. Backed by accurate, scientific information, the SCDC program can inform
stakeholders about how these gaps can be filled through policy changes, improved health care practices, and
new therapies. Stakeholders who can drive changes in action from knowledge gained from the SCDC data
set include individual health care providers, health systems, policymakers, payers, and affected populations
(patients and their support circles).
CDC, in partnership with stakeholders, established five priority areas for SCDC to address.63
Where people with SCD live
SCDC data shows where patients, health care providers,
and health care facilities are geographically located and
can help answer questions related to access, health care
utilization, and quality of care.
The data allows examination of geographic challenges
in gaining access to care, how far patients travel
for treatment, whether they are seen at the closest
facilities to their home, the ratio of identified patients
to services or providers in a given region, and how
these geographical factors may influence utilization by
provider type (e.g., ED) and if local providers treat SCD
patients according to best practices.

National SCDC Priority Areas
 Aging population
 Geography of population
 Hispanic SCD population
 Transition
 Utilization

Transition from pediatric to adult care
SCDC data includes information on utilization (i.e., how many times a patient visits specific types of providers
or settings, treatments, and procedures) and health outcomes for most patients within a state, whether or not
they are seen in an SCD clinic regularly.
Previous research has shown that the period of transition from pediatric to adult care coincides with the onset
of the increasing symptom severity and high health care utilization, even for patients in regions with highquality pediatric care. SCDC data enables examination of the factors (e.g., geography, access to care, insurance
status, preventive care) that may be associated with increases in SCD symptoms and complications and poorer
outcomes that surface during the transition to adult
care.
Hispanic patients
SCDC data includes reliable information on ethnicity
and race from patients with linked newborn
screening and clinical case reports. Studies estimate
that about 10% of patients with SCD in the United
States are Hispanic.64  SCDC enables analysis of
variables (e.g., geography, utilization, and outcomes)
through the lens of Hispanic ethnicity.
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Older patients
SCDC data includes longitudinal data on middle-aged
patients and can reliably determine SCD status even
among patients who have relatively few SCD-related
health system encounters. Additionally, SCDC data
includes death records, with identified cause of
death.
People with SCD are living longer, so we have the
opportunity to study them as they become older
adults.10 Previous research has shown that in an
SCD cohort, complications and comorbidities were
common and included hypertension and diabetes,
as well as early-onset complications, such as chronic renal disease, iron overload, and cardiovascular disease.52
Additionally, the majority were not undergoing routine, recommended cancer screenings. SCDC data enables
documentation of complications and outcomes during the life course, which can inform development of
standards of care, interventions, and health care policy to serve this population.
Use of health care services
SCDC data includes longitudinal health care utilization information by patient and across patients. Utilization
measures include counts of ED visits, outpatient visits (for those on Medicaid), visits by type of provider, and
hospitalizations.
Previous research has been limited in its capacity to examine all forms of health care utilization. There have
been some studies describing ED utilization (29% of SCD patients had no ED visits or hospitalizations while
16.9% had three or more per year), looking at age at time of heightened health care utilization (e.g., during
transition between pediatric and adult care), and factors associated with higher utilization (e.g., age, disease
severity, greater parental education, and psychiatric illness).26, 51, 52, 65 SCDC data enables comparisons between
low and high utilizers by diagnosis, procedure or intervention, and outcomes. It can also examine events or
complications that precede periods of high utilization. Such analysis may inform practice behavior and patient
self-care associated with improved outcomes at reduced costs.

Analysis And Dissemination Planning For Georgia
Guiding framework
The Georgia SCDC project set out to create a three-year plan for analysis and dissemination activities that was
both stakeholder-informed and action-oriented. These principles help ensure the project’s goal that use of this
longitudinal data can inform changes in policies and practices that ultimately improve length and quality of life
for SCD patients. We engaged a broad cross section of stakeholders in the planning process to provide as many
perspectives and insights as possible into the potential for SCDC data to impact change and to build awareness
and support for future analysis and dissemination activities. The identified stakeholders serve both as research
design partners and audience for research outputs.
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These guiding principles of having a stakeholderinformed and action-oriented plan aligned closely
with those of the Patient-Centered Outcomes
Research Institute (PCORI), so we developed a
modified version of PCORI’s Dissemination and
Implementation Framework to guide our own work.66
PCORI’s mission is to drive informed health care
decisions and improve health care delivery and
outcomes by producing and promoting high-integrity,
evidence-based information.67  Central to this mission
is PCORI’s tenent that those most likely to use the
information should help guide the research process.
To be effective, dissemination and implementation activities must reflect the needs and concerns of end users.
PCORI’s Dissemination and Implementation Framework illustrates this commitment to increase the awareness
of evidence and promote its integration into practice. The framework focuses on ways to enhance awareness
and knowledge of useful and relevant information (dissemination) to help people and organizations make
decisions and put it into practice (implementation).
Effective knowledge-sharing starts at the point of research topic selection by recognizing the need to
understand the priority questions that can inform practice and improve outcomes and to identify the
audiences who will use this evidence to make relevant decisions. PCORI defines the key components of this
cycle as:66
•

Stakeholders — All people and organizations with a vested interest in increasing the quantity, quality,
and timeliness of useful, trustworthy information to support health and health care decisions;

•

Dissemination — The active process of identifying target audiences and tailoring communication
strategies to increase awareness and understanding of evidence, and to motivate its use in policy,
practice, and individual choices; and

•

Implementation — The iterative process of integrating evidence into policy and practice through
adapting evidence to different contexts and facilitating behavior change and decision making based on
evidence among individuals, communities, and health care systems.

Georgia SCDC’s modified version of the PCORI Dissemination Framework is shown in Figure 5.
The framework is presented as a set of concentric cycles, showing that the use of data to inform change is an
iterative process that repeats as objectives are met, new findings emerge, or important contextual changes
develop. The outer cycle reflects the overall steps: identify and prioritize information needs, produce the
data and analysis, and provide quality, targeted information – ultimately to improve health, well-being, and
longevity among people wih SCD. The inside cycle describes the steps in greater detail, with questions framing
the objectives for each. “Engage individuals, organizations, and communities” is at the center, reflecting that
stakeholders have roles throughout the cycle.
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Figure 5. A Framework Linking Dissemination to Action and Results

Adapted from Esposito, D., Heeringa, J., Bradley, K., Croake, S., Kimmey, L. (2015). A framework linking dissemination to action and results [Flow Chart]. PCORI
Dissemination & Implementation Framework. Retrieved from http://www.pcori.org/sites/default/files/PCORI-Dissemination-Implementation-Framework.pdf

Sickle cell stakeholder convening
Figure 6 illustrates the process the Georgia Health Policy Center used to develop the three-year dissemination
and analysis plan for SCDC Georgia — determining needs, identifying audience and partners, and beginning to
inform dissemination, action, and assessment.
The five topic areas identified as SCDC priorities nationally provided an initial foundation for the plan.
Stakeholders were engaged at to help develop the three-year plan for Georgia through a smaller “design
team” representing a microcosm of SCD stakeholders and in a day-long convening of diverse stakeholders (see
Appendix A).
Design team members were recruited to help shape the convening and make sense of its results. In the
months prior to the convening they met three times, providing insights, perspectives, and advice in response
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to evolving drafts on the convening’s purpose, intended outcomes, target stakeholder groups, invitation list,
and agenda. The project team at the Georgia Health Policy Center incorporated input and arranged meeting
logistics.
The meeting was designed to produce the following:
1. Stakeholder input for Georgia’s three-year dissemination and analysis plan;
2. Increased awareness and understanding of Georgia’s SCDC data set; and
3. New and stronger connections among SCD stakeholders in Georgia.
Figure 6. Development of Georgia SCDC Three-Year Analysis and Dissemination Plan

National
SCDC
Priorities

Framework
for GA
SCDC Plan

1st
Draft

2nd
Draft

Final
Plan

Design
Team

Design
Team

Stakeholder
Group*

Stakeholder
Group

Key:
Synthesis/drafting by the Georgia Health Policy Center team
* Stakeholder group also includes design team and national project sponsors

Stakeholder groups identified for engagement fell into three broad categories: those affected by SCD (e.g.,
patients, caregivers, community-based organization representatives); providers (e.g., outreach workers,
clinic nurses, primary care and emergency physicians, pediatric and adult hematologists, pharmacists, and
health system representatives); and decision makers/decision informers (e.g., elected officials and legislative
staff, public and private payer representatives, public health personnel, health services researchers, research
funders, pharmaceutical industry representatives, and health communicators).
A total of 49 individuals participated in the day-long convening, held outside of Atlanta, Ga. on May 11, 2017.
Attendees’ 24 organizational affiliations are listed in Appendix A). Participants included seven patients with
SCD, four family members of SCD patients, 12 in public health, 13 clinicians, 17 researchers, nine from funding
entities, three in public policy roles, three from the insurance industry, and six from the pharmaceutical
industry.¹  Participants were assigned seats at tables designed to optimize the mix of perspectives. After a
background presentation on SCD surveillance efforts and orientation to the SCDC data set, the remainder of
the day was spent in focused table conversations or whole-room feedback and discussion. Input was captured
on individual worksheets and table flip charts.
After the convening, Georgia Health Policy Center staff compiled and organized the output, identified themes,
and developed a rough plan draft that was reflected back to the design team for input in a final meeting. That
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feedback was then incorporated and a second draft shared with the full group of convening participants for
final review and comment. What follows is the result of that process.

Georgia Priorities, 2017-2020
Definitions of key variables
Stakeholder groups
•

Affected populations: Patients, caregivers,
representative community-based
organizations.

•

Health systems: Organizations participating in
the local system of care.

•

Payers: Public and private entities responsible
for paying for health care and defining enrollee benefits.

•

Providers: Direct care providers, such as outreach workers, clinic nurses, primary care physicians, ED
physicians, and hematologists.

•

Policymakers: Those responsible for broad-level resource allocation decisions.

It should be noted that additional stakeholders (including research funding agencies, philanthropies, and
pharmaceutical companies) may find SCDC data analysis useful. The five selected stakeholders reflect the
broadest groups with the most widespread use for SCDC data analysis. However, partnerships with other
groups would be valuable and welcome.
Actions that could be informed by SCDC analysis and dissemination
•

Educate: To shape institutional or individual practices, behaviors, or attitudes.

•

Decide: To inform policy or resource allocation decisions or plans.

•

Learn: To answer research questions in order to inform future actions.

•

Target: To define a population for receipt of interventions, services, or education.

Nationally identified SCD priority areas (previously defined in more detail on p. 18)
•

Aging: Population of SCD patients reaching midlife and beyond.

•

Geography: Demographic-related data, with a particular emphasis on location.

•

Hispanic: Those with self-identified Hispanic ethnicity.

•

High utilization: Those using higher levels of health care services.

•

Transition: SCD patients moving from pediatric to adult services.

Fitting SCD priorities in the national health reform landscape
Efforts are underway locally, regionally, and nationally to transform the health care system to be more efficient,
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equitable, and effective. The Triple Aim, as originally
defined by the Institute for Healthcare Improvement
in Cambridge, Mass., refers to the simultaneous
pursuit of improving the patient experience of care
(quality of care), improving the health of populations
(overall outcomes), and reducing the per capita cost
of health care. In recognition of these goals, Georgia
SCDC mapped priorities to three key components of
the Triple Aim: access, cost, and quality.
Access
Inherent in the pursuit of the Triple Aim is the
assumption that patients are able to access health
care. SCDC data includes measures of many
components of access, including geography (the distribution of SCD patients in the state and distribution and
types of SCD care providers throughout the state), and insurance status of patients. Other SCDC demographic
data (e.g., age, race) may also be helpful in identifying any gaps in access to appropriate care.
Cost
Containing cost and increasing value is a pervasive theme of health care reform efforts. Public and private
payers are in many cases tying reimbursement to the quality of care provided in order to ensure that care is
effective, efficient, and coordinated. The focus on quality of care is placing more emphasis on evidence-based
medicine and standardizing care as a way of enhancing quality and reducing disparities. As patients are footing
an increasing share of health care bills, they too are starting to pay more attention to the cost of care.
SCD care is costly and plagued with substantial practice variation.32 Based on a multistate, multipayer patient
sample, SCD-attributable medical expenditures in children were conservatively estimated in 2005 to cost $335
million.68  Children with SCD incurred medical expenditures that were $9,369 and $13,469 higher than those
of children without SCD enrolled in Medicaid and private insurance, respectively, or six and 11 times those of
children without SCD enrolled in Medicaid and private insurance, respectively.68 Care is even more costly in
adults. Total health care costs with SCD rise with age, from $892 to $2,562 per patient-month in the 0-9–year
and 50-64–year age groups, respectively.69
Extrapolated, the average lifetime of care for an SCD patient is $460,151. The same study showed that the
majority of SCD-related health care costs (80.5%) are associated with inpatient hospitalizations. Stakeholders
believe that interventions that can prevent SCD complications and hospitalizations have the potential to reduce
the significant economic burden of the disease. Additionally, improving access to care and educating patients
about appropriate care seeking (including self-care) based on symptoms also have the potential to cut SCDrelated costs.
Quality
While the effectiveness of certain prophylactic treatments (hydroxyurea and penicillin) and screenings (TCD)
have been documented in the literature, the adoption of these advances into routine clinical care is often
lengthy.70  Implementation of evidence-based practice standards has been shown to improve quality of care for
patients with SCD, but, again, there are questions about whether this quality care is reaching all SCD patients.71
Longitudinal SCDC data enables evaluation of the adoption of these promising practices in real-life settings,
both in terms of provider behavior and impact on patient outcomes.
24

Figure 7. SCDC Georgia Plan Aligned With Dissemination Framework

The three-year analysis and dissemination plan for SCDC Georgia elaborates upon the elements of the
Framework Linking Dissemination to Action and Results. The nationally identified SCDC priority areas served
as a starting point for stakeholder-identified needs; the Design Team and the broader Stakeholder Group
served as the audience and partners; the actions that can be informed by SCDC dissemination and analysis, as
identified by the convening participants parallel actions; and the elements of the triple aim were selected as
high-level parameters of impact.

Recommended dissemination activities
The convening yielded an extensive list of stakeholder-identified needs and potential actions that can be taken
by multiple audiences as a result of SCDC data and analysis. The full list of Georgia SCDC priorities identified by
convening attendees is displayed in Appendix B.
The Georgia SCDC team distilled the full list by:
•

What is feasible with the data set;

•

What is actionable by one or more stakeholder groups toward improving length or quality of life;

•

The timeframe (short-term dissemination not requiring extensive analysis and longer-term, more
complex research questions); and

•

Priorities within the SCD community.
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Affected Populations
Target patient materials on SCD basics and appropriate use of health care through
hospitals and emergency departments in parts of state with high utilization
Target SCD patient and family education in parts of state with high SCD prevalence,
high SCD-related mortality, high complication rates, or unusual utilization patterns
Target high-incidence areas for trait education and screening
Target culturally, linguistically, and topically appropriate patient outreach and
education based on patient demographics by geography
Health Systems
Target outreach/case management capacity (and ultimately workforce/hiring
decisions) based on areas of greatest service shortage, especially to ensure access to
essential follow-up
Decide allocation of outpatient resources/hours based on the most frequent
presenting reasons for ED visits/hospitalizations
Decide location and hours of specialty clinics and establishment of telehealth
capabilities based on accessibility of care facilities across the acuity spectrum
Payers
Decide quality measures to reflect evidence-based practices
Target transition-appropriate information on health, benefits, and referrals based on
areas of highest transition-aged populations
Target provider contracts to ensure in-network care options (or out-of-network
coverage if no other option) for all ages, needs, acuities available within reasonable
time and distance of patients
Policymakers
Decide resource allocation to make social services and supports accessible, based on
distribution of births and transition-aged and aging populations
Decide workforce development incentives to reduce provider-patient gaps by
geography
Target benefits counseling and referrals for parents of newborns, transition-age
patients, and adult patients based on incidence/prevalence distributions by age
Providers
Target education of emergency physicians, primary care providers, OB/GYNs, and
hospitalists in areas with high incidence, prevalence, mortality, or utilization
Decide referral strategies based on location of specialists and SCD care providers
Target culturally, linguistically, and topically appropriate provider education based
on demographics by geography
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Utilization

Transition

Hispanic

Geography

Target Audience

Aging

Table 1. Three-Year Dissemination Opportunities by Target Audience and Priority Area

Table 1 reflects the top, short-term dissemination opportunities that can be completed using Georgia SCDC
within a three-year timeframe. These prioritized dissemination needs are sorted by stakeholder audience and
how they target national SCDC priorities.
The dissemination activities listed in Table 1 hinge on Georgia SCDC data outputs summarized in Table 2.
Maps and tables of key variables by geography will be among the first products in the three-year plan, with
additional variables by geography produced as requested by end users. Presenting reasons and qualityassociated practice measures are targeted for Year 2. While the project team will proactively produce certain
of these outputs and will solicit queries from and partner with stakeholder groups, those groups carry the
primary responsibility for strategically disseminating the evidence provided and driving the desired actions.

Providers

Policymakers

Payers

SCDC Data Outputs

Health System

Affected Population

Table 2. Three-Year Georgia SCDC Data Outputs

Geography of patient demographics (age, race/ethnicity, language)
Geography of utilization (areas of high incidence, prevalence,
mortality, and/or utilization)
Geography of providers (locations of SCD care providers and
specialists; care facilities across the acuity spectrum)
Most frequent presenting reasons for emergency visits and
hospitalizations
Quality measures for evidence-based practices

High-priority data analysis topics
Some of the needs and opportunities convening stakeholders identified require longer-term, more complex
analysis of Georgia SCDC data. The Georgia SCDC team removed analysis requests that were not feasible with
the data set and then worked with the design team to identify priority research questions — those of greatest
immediate need and potential to impact change. Design team members also noted that priority should be
given to questions that our longitudinal data is uniquely suited to answer, ones that have not been well studied
to date, and ones that the patient/caregiver community has voiced as concerns.
The resulting priorities are grouped into three analysis topics: complications and utilization across the  
pediatric-to-adult transition, pain treatments and opioid usage, and complications and comorbidities in the
aging population. Table 3 demonstrates how the analysis priorities can inform action and address the national
SCDC priorities.
Initial studies in each of the three areas can begin in Year 1, with follow-up analysis in subsequent years
determined according to availability of resources, evolving findings and new results in the field, and ongoing
stakeholder input.
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Pain treatments and opioid usage:
• Who is prescribing pain medicine for SCD patients?
• Where and how often are these prescriptions being
filled?
• What treatments are associated with lower opioid
prescribing?
• Does mental health service consultation reduce opioid
prescribing or use?

Policies and practices for
patients, pharmacies,
providers, and EDs.

Complications and comorbidities in the aging SCD
population:
• What are the patterns in complications and
comorbidities in the aging SCD population by patient
variables (e.g., genotype, race, geography)?
• What complications are predictive of mortality in
different age groups?
• What complications are associated with pregnancy?
• What are the patterns in complications for women
from pre- to post-menopause?

Practice
recommendations for
primary and specialty
care of adults

Utilization

Decisions on health
insurance coverage
extensions for young
adults and other
transition-supportive
policies and practices

Transition

Complications and utilization across pediatric-to-adult
transition:
• What are the patterns in complications and
health care utilization (e.g., transfusion frequency,
prescription filling, outpatient visits, emergency
department visits) across transition?
• How do these patterns relate to insurance status, age,
race/ethnicity, geography?

Hispanic

Actions to Be Informed

Geography

Research Questions

Aging

Table 3. Priority Analysis Topics by Action and Priority Area

The convening stakeholders identified a wealth of relevant research questions that, given capacity and funding,
Georgia SCDC would like to address. Analysis topics not put in the first tier for the three-year plan, but deemed
important and doable with SCDC data, are listed below.
Utilization
•
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Are there patterns of complications associated with higher utilization/mortality? What factors are
associated with hospital readmissions? What factors are associated with use of multiple emergency
departments or multiple health systems? Are there early signs of complications that could inform
patient self-care practices? Can we identify people who are at high risk for preventable, poor outcomes?

•

What is the cost-effectiveness of treating SCD patients in a day hospital setting? Are there differences in
morbidity/mortality by usual care setting or by access (cost/coverage) to specialists; to a comprehensive
care center; to behavioral health care? Are there differences in utilization (ED, hospital, preventive
services) by type of primary SCD provider (specialist or generalist)? Do those frequently using the ED
have a primary source of SCD care?

•

Are there differences in utilization types/frequencies by geographic distance? Does distance contribute
to use of ED vs outpatient care? Are there SCD patients not seen regularly or unable to keep
appointments for whom distance or transportation might be a key barrier?

Other
•

Describe the overall cost burden of SCD. How does cost vary by patient demographics? What is the
long-term cost-benefit of investment in preventive strategies? Describe ER cost-effectiveness to
support the need for enhanced outpatient services. Can ED visits be mitigated through improved case
management? Should payment be tied to outcomes?

•

What are the trends over time in providers’ adherence to recommended practices? Are there commonly
used treatments that are not associated with better outcomes? Do new treatments have long-term
implications for mortality and other outcomes?

•

How is it best to manage the needs of dual beneficiaries?
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Appendix A: Organizations Represented by
Convening Attendees
A representative invitee list was initially developed by the design team. If invitations were declined, invitees
were encouraged to refer others from their organization in order to achieve balance and ensure that
representative stakeholders were present at each working table.
A total of 49 stakeholders, representing 24 different organizations, participated in the convening. Stakeholders
attending the May 11, 2017, Sickle Cell Stakeholder Convening in Atlanta were roughly evenly representative
of three broad categories: those directly affected by SCD (e.g., patients, caregivers, and representative
community-based organizations), providers (e.g., outreach workers, clinic nurses, primary care, ED physicians,
and pediatric and adult hematologists), and decision makers/decision informers (e.g., health services
researchers, health communicators, public health personnel, payers, research funders, and legislators). The list
of represented organizations follows.
Alliant Quality

Georgia House Budget and Research Office

Amerigroup/Anthem

Georgia House of Representatives (Budget and Research Office)

Association of University Centers on Disabilities

Georgia Southern University, College of Public Health

Augusta University

Global Blood Therapeutics

Bioverativ

Grady Health System

CDC

Medical College of Georgia, Augusta University

CDC Foundation

Peach State Health Plan

Children’s Healthcare of Atlanta

Pfizer

East Central Regional Hospital

Sickle Cell Awareness Ride

Emory University

Sickle Cell Community Consortium

Georgia Department of Public Health

University of Maryland, School of Medicine

Georgia Health Policy Center, Georgia State University WellCare of Georgia Inc.

Discussion at the convening surfaced additional stakeholders whose participation should be sought. These
stakeholders categorically include:
AARP

Media and celebrities

American Society of Hematology

Medical students and other emerging professionals

Cultural liaisons

Mental health community

Ga Department of Community Health

Palliative care community

Ga Department of Human Services

Patient advocacy (national representatives)

Faith-based community

Primary care

Hospital association

Rural area representatives

Immigrant and refugee community

Social workers and case managers

Legislators from the Health and Human Services and
appropriations committees

Sororities and fraternities
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Affected Populations

Health Systems

Georgia Health Policy Center

Decide: Location
and hours of
clinics, referral
strategies based
on distance
patients drive to
access care in
outpatient clinics

Target:
Outreach/case
management
capacity in areas
of need/service
shortage

Study: Do
outcomes vary by
setting of shortterm crisis
management?

Target: Transitionage patients with
benefits
counseling

Target:
Workforce/hiring
decisions based
on ratio of
patients to
hematologists by
geography

Decide: Inform
location of
specialty clinics
and
establishment of
telehealth
capabilities
based on access
to care facilities
across the acuity
spectrum

Educate: About
record-keeping
and
communicating
with non-usual
care physicians

Utilization

Target: Education
of school
nurses/university
student health
centers

Access

Insurance

Educate: About
appropriate
acuity of care to
seek for various
clinical scenarios

Health
System
Design

Target: Education
for
patients/families
on transition
planning

Geography

Decide:
Allocation of
outpatient
resources/hours
based on the
most frequent
presenting
reasons for ED
visits/
hospitalizations

Target:
Materials/staff
training for
patients on SCD
basics and
appropriate use
of health care at
EDs where there
is high utilization
or a number of
individual highutilizers

Appropriate
level of care

Study: Biggest
health
concerns/lessons
for transitioning
youth to inform
self-care
practices

Target: Highincidence areas
for Trait
education and
screening

Educate: On best
practices for selfcare and
prevention

Cost

Return on
investment

Decide: Case
management
based on mostpreventable
readmissions

Study: Who is at
high risk of
preventable,
poor outcomes
to inform patient
self-care
practices

Study: Early signs
of complications
to inform patient
self-care
practices

Outcomes

Utilization

Opioid
Rx

Decide: Establish criteria Study:
for or use data to justify Medication
Center of Excellence
adherence
status or other
recognition for excellent
SCD care

Decide: Self-care and
self-advocacy practices
based on what to expect
- most common
complications by age,
sex, genotype

Quality

Recommendations

Decide:
Resource
allocation to
address
greatest
disparities in
outcomes - by
race,
geography,
insurance,
other

Disparity

Appendix b: Undistilled Georgia SCDC Priorities
Identified by Convening Attendees
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Payers

Policymakers
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Decide:
Incentivize
workforce
development
based on
provider/patient
gaps

Decide: Planning
and resource
allocation based
on prevalence
distribution for
different ages of
SCD population.
Do certain areas
need to plan for
transition-age,
older SCD
patients? Identify
areas likely to
need other social
services,
supports,
outreach,
transportation.

Target: Outreach
to cultural,
language, and
documentation
status
demographics

Target: Education
of non-specialist
providers, if
specialists are
not in close
proximity

Health
System
Design

Target: Contracts
to ensure innetwork care
options for all
ages, needs,
acuities are
available within
reasonable
geographic
distance

Geography

Target: Benefits
counseling and
referral for
parents of
newborns,
transition-age
patients and
adult patients

Decide: Over-age
coverage
extensions based
on transition-age
needs, outcomes,
costs

Target:
Appropriate
referrals and
benefits
counseling for
transition-age
patients

Insurance

Target: Patients
without usual
care for referral,
case
management

Target: Case
management to
those unable to
access the
appropriate
acuity of care

Decide: Need for
enhanced
outpatient
services based on
ER costeffectiveness

Utilization
Target: Education
for providers
whose patients
are higher
utilizers of
emergency
departments

Appropriate
level of care

Return on
investment
Decide: Case
management
based on stats
about
preventable
readmissions

Outcomes

Utilization
Decide: Establish quality
measures associated
with evidence-based
practice

Recommendations

Opioid
Rx
Disparity
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Providers

Target: Education
of emergency
physicians,
primary care
providers,
ob/gyns in highprevalence areas

Geography

Educate: Inform
referral
strategies. Where
are specialist SCD
care providers
located?

Health
System
Design
Insurance

Utilization

Target: Education
of providers in
areas with more
frequent ED
utilizers

Educate: Improve
discharge/selfcare planning
with patients
based on the
most frequent
presenting
reasons for ED
visits and
hospitalizations

Appropriate
level of care

Target: Education
strategies based
on areas of
practice where
standards are
least followed

Educate:
Improve uptake
of best practices
in preventive
care, based on
stats on
preventive care
and
consequences

Return on
investment
Outcomes

Utilization

Recommendat
Opioid Rx
ions
Disparity
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